DIVISLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | DIVISLAB | Market Cap | 1,72,621 Cr. | Current Price | 6,502 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 67.1 | Book Value | 578 ₹ | Dividend Yield | 0.46 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,220 ₹ | DMA 200 | 6,216 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 66.1 | MACD | 103 | Volume | 3,93,137 | Avg Vol 1Wk | 3,35,462 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | -7.29 | Debt to equity | 0.01 |
| 52w Index | 60.1 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 30.1 |
📊 Divi’s Laboratories (DIVISLAB) demonstrates strong fundamentals with ROE (15.6%) and ROCE (20.6%), supported by a virtually debt-free balance sheet (Debt-to-equity 0.01). EPS of ₹94.8 reflects robust earnings power, and dividend yield of 0.46% adds shareholder value. Quarterly PAT declined slightly (696 Cr → 653 Cr), but overall profitability remains healthy. Valuation is stretched with P/E (67.1) compared to industry average (30.1), while PEG ratio (-7.29) signals poor growth-adjusted value. Technicals remain bullish with RSI (66.1), MACD (103), and price trading above both 50 DMA (6,220 ₹) and 200 DMA (6,216 ₹).
🎯 Entry Zone: 6,150 ₹ – 6,250 ₹ (near DMA support)
📌 Long-Term Holding: Suitable for 2–3 year horizon. Strong fundamentals justify accumulation, though valuations warrant cautious exposure. Upside potential exists toward 6,800–7,000 ₹, with partial profit booking advisable on overbought signals.
Positive
- Strong ROE (15.6%) and ROCE (20.6%) highlight efficiency.
- Virtually debt-free balance sheet ensures financial resilience.
- EPS of ₹94.8 supports earnings visibility.
- FII holdings increased (+0.21%), showing foreign investor confidence.
- Technical indicators (RSI, MACD) show bullish momentum.
Limitation
- High P/E (67.1) compared to industry average (30.1).
- Negative PEG ratio (-7.29) indicates poor growth-adjusted valuation.
- Quarterly PAT decline (696 Cr → 653 Cr).
- DII holdings decreased (-0.05%), showing reduced domestic institutional support.
Company Negative News
- Slight decline in quarterly PAT raises concerns about earnings momentum.
- Valuation risks remain elevated compared to peers.
Company Positive News
- Strong efficiency metrics with virtually no debt.
- FII inflows highlight foreign investor confidence.
- Technical strength above DMA levels supports bullish sentiment.
Industry
- Industry P/E (30.1) is much lower than DIVISLAB’s 67.1, highlighting premium valuation.
- Pharmaceutical sector remains resilient, supported by global demand for APIs and specialty formulations.
Conclusion
⚡ Divi’s Laboratories is fundamentally strong with efficient capital use and virtually no debt. Entry around 6,150–6,250 ₹ offers favorable risk-reward. Long-term holding is justified with cautious accumulation, though valuations warrant discipline. Partial profit booking near 6,800–7,000 ₹ is advisable, with exit below 6,100 ₹ on heavy volume.
This structured HTML report captures Divi’s Laboratories’ strong fundamentals alongside its valuation risks. If you’d like, I can extend this into a peer benchmarking overlay against other pharma players like Sun Pharma or Dr. Reddy’s to highlight relative positioning. Would you like me to prepare that next?